EKSO vs. ITRM, LSTA, ADXN, ONCT, DRRX, INDP, IINN, GDTC, HLTH, and BFRG
Should you be buying Ekso Bionics stock or one of its competitors? The main competitors of Ekso Bionics include Iterum Therapeutics (ITRM), Lisata Therapeutics (LSTA), Addex Therapeutics (ADXN), Oncternal Therapeutics (ONCT), DURECT (DRRX), Indaptus Therapeutics (INDP), Inspira Technologies Oxy B.H.N. (IINN), CytoMed Therapeutics (GDTC), Cue Health (HLTH), and Bullfrog AI (BFRG). These companies are all part of the "medical" sector.
Iterum Therapeutics (NASDAQ:ITRM) and Ekso Bionics (NASDAQ:EKSO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Iterum Therapeutics has a net margin of 0.00% compared to Iterum Therapeutics' net margin of -83.14%. Iterum Therapeutics' return on equity of -90.80% beat Ekso Bionics' return on equity.
In the previous week, Ekso Bionics had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Ekso Bionics and 0 mentions for Iterum Therapeutics. Ekso Bionics' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.
Ekso Bionics received 182 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. However, 61.93% of users gave Iterum Therapeutics an outperform vote while only 57.43% of users gave Ekso Bionics an outperform vote.
Iterum Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 287.10%. Ekso Bionics has a consensus price target of $9.25, suggesting a potential upside of 683.90%. Given Iterum Therapeutics' higher probable upside, analysts clearly believe Ekso Bionics is more favorable than Iterum Therapeutics.
Iterum Therapeutics has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500. Comparatively, Ekso Bionics has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.
Ekso Bionics has higher revenue and earnings than Iterum Therapeutics. Ekso Bionics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.
9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 6.4% of Ekso Bionics shares are held by institutional investors. 5.4% of Iterum Therapeutics shares are held by insiders. Comparatively, 7.5% of Ekso Bionics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Ekso Bionics beats Iterum Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Ekso Bionics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EKSO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EKSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ekso Bionics Competitors List
Related Companies and Tools
